Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 12Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Prostatic Neoplasms 4Solid Tumor 3Neoplasm Metastasis 3Melanoma 3Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Choledocholithiasis 2Carcinoma 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Terminal Cancer 1Synovitis, Pigmented Villonodular 1Stomach Neoplasms 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Skin Neoplasms 1Respiratory Aspiration 1Respiration Disorders 1Rectal Neoplasms 1Rare Diseases 1Prostate Cancer Patients 1

Interventions

ceritinib 1Warfarin 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ALK-positive Advanced Tumors × Midazolam × Clear all
NCT02422589 2020-12-19

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Novartis

Phase 1 Completed
33 enrolled

ALK-positive Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡